ECCMID 2023 Archives

Antimicrobial Susceptibility Testing: The Joint Efforts of CLSI and EUCAST丨ECCMID 2023

By Lisa Cui 2024.01.15

Antimicrobial susceptibility testing (AST) is pivotal in both individualized and empirical treatments. Notably, standards set for interpreting AST results enable clinicians to choose suitable medications and optimal treatment plans, acting as a significant tool in controlling antimicrobial resistance. The most influential bodies in this space are the Clinical and Laboratory Standards Institute (CLSI) of the United States and the European Committee on Antimicrobial Susceptibility Testing (EUCAST). These entities aim to standardize AST procedures and reduce experimental errors.

Interview with Chao Zhuo at ECCMID 2023

By El Bachir MOURABIT 2024.01.15

The 33rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) took place in Copenhagen, Denmark, from April 15th to 18th, 2023. As one of the most significant conferences in the field of clinical microbiology and infectious diseases, it marked a significant gathering after a three-year hiatus due to the pandemic. Chinese experts, including Dr. Chao Zhuo from The First Affiliated Hospital of Guangzhou Medical University, were present to share their insights.

Interview with Minggui Wang at ECCMID 2023

By Peter W. PENG 2023.10.23

The 33rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) recently took place in Copenhagen, Denmark, drawing attention as one of the first major in-person events since the easing of the COVID-19 pandemic. The event, a hallmark in the world of infectious diseases and clinical microbiology, attracted numerous participants, among whom was Dr. Minggui Wang, the director of the Institute of Antibiotics, Huashan Hospital, Fudan University. Dr. Wang shared insights on the advances and experiences at the conference, with a particular focus on fungal infections.

Dr. Michelle Seif: CAR-T Therapy’s Potential in Treating Fungal Infections丨ECCMID 2023

By Peter W. PENG 2023.10.23

At the 33rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2023), the prospect of utilizing Chimeric Antigen Receptor T-cells (CAR-T) for medical treatments has emerged as a promising avenue, especially in the realm of infectious diseases. Notably, Dr. Michelle Seif from the University Hospital Würzburg, Germany, has presented new findings that expand upon the potential use of CAR-T therapy in fungal infections.

Dr. José Luis Del Pozo: The Fight Against Gram-Positive Bacterial Infections丨ECCMID 2023

By Peter W. PENG 2023.10.23

In an era where antibiotic-resistant infections like MRSA are on the rise, healthcare professionals are constantly in search of potent drugs to combat these pathogens. The 33rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2023) presented an opportunity to explore advancements in this area. One of the notable voices at this congress was Dr. José Luis Del Pozo from the University of Navarra. Infectious Disease Frontline had a chance to sit down with him for a comprehensive discussion.

Antimicrobial Susceptibility Testing: Insights from EUCAST Pioneer, Dr. Gunnar Kahlmeter丨ECCMID 2023

By Peter W. PENG 2023.10.23

Antimicrobial susceptibility testing (AST) is critical in modern medicine, helping doctors determine which antibiotics are most likely to be effective against particular bacterial infections. Across the globe, standards for AST primarily revolve around the European EUCAST and the American CLSI. Dr. Gunnar Kahlmeter, one of the main architects of EUCAST, offers unique insights into the past, present, and future of AST.

Dr. Anne J. Gonzales-Luna: Progress in Pediatric Clostridioides difficile Infection丨ECCMID 2023a

By Peter W. PENG 2023.10.23

Clostridioides difficile, a primary cause of antibiotic-associated diarrhea, presents a spectrum of clinical manifestations. While less prevalent in children than adults, the incidence of pediatric Clostridioides difficile infection (CDI) is on the rise. The 33rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2023) dedicated a session to shed light on this pressing issue, with Dr. Anne J. Gonzales-Luna from the University of Houston College of Pharmacy offering her expertise.

Dr. Xiaoting Hua: Groundbreaking Findings on Cefiderocol Resistance in Acinetobacter baumannii 丨ECCMID 2023

By Peter W. PENG 2023.10.12

At the 33rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2023) held in Copenhagen, Dr. Xiaoting Hua of the Sir Run Run Shaw Hospital affiliated with Zhejiang University School of Medicine unveiled significant findings. His research focused on mutations that mediate Acinetobacter baumannii's resistance and virulence to a new antibiotic, Cefiderocol.

Dr. Yimin Wang: Advances in Ventilator-Associated Pneumonia Research丨ECCMID 2023

By Peter W. PENG 2023.10.12

Ventilator-Associated Pneumonia (VAP) continues to be a critical concern in intensive care units, leading to prolonged hospital stays and increased mortality rates. The European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2023 unveiled crucial research findings shedding light on innovative approaches to VAP diagnosis and treatment. In this article, we present a synthesis of the key discoveries from ECCMID 2023, offering insights into the evolving landscape of VAP research.

Interview with Chao Zhuo at ECCMID 2023

By Peter W. PENG 2023.10.12